0001140361-14-046592.txt : 20141229 0001140361-14-046592.hdr.sgml : 20141225 20141229174029 ACCESSION NUMBER: 0001140361-14-046592 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20141223 FILED AS OF DATE: 20141229 DATE AS OF CHANGE: 20141229 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9143477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sanofi CENTRAL INDEX KEY: 0001121404 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] STATE OF INCORPORATION: I0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 141313637 BUSINESS ADDRESS: STREET 1: 54 RUE LA BOETIE CITY: PARIS STATE: I0 ZIP: 75008 BUSINESS PHONE: 33153774400 MAIL ADDRESS: STREET 1: 54 RUE LA BOETIE CITY: PARIS STATE: I0 ZIP: 75008 FORMER NAME: FORMER CONFORMED NAME: SANOFI-AVENTIS DATE OF NAME CHANGE: 20040826 FORMER NAME: FORMER CONFORMED NAME: SANOFI SYNTHELABO SA DATE OF NAME CHANGE: 20010104 4 1 doc1.xml FORM 4 X0306 4 2014-12-23 0 0000872589 REGENERON PHARMACEUTICALS INC REGN 0001121404 Sanofi 54, RUE LA BOETIE PARIS I0 75008 FRANCE 0 0 1 0 Common Stock 2014-12-23 4 P 0 1190 384.4259 A 22658875 I See note Common Stock 2014-12-23 4 P 0 16813 385.5228 A 22675688 I See note Common Stock 2014-12-23 4 P 0 17013 386.4523 A 22692701 I See note Common Stock 2014-12-23 4 P 0 5500 388.0395 A 22698201 I See note Common Stock 2014-12-23 4 P 0 15104 389.1733 A 22713305 I See note Common Stock 2014-12-23 4 P 0 12046 389.8806 A 22725351 I See note Common Stock 2014-12-23 4 P 0 2550 391.2539 A 22727901 I See note Common Stock 2014-12-23 4 P 0 8030 392.9571 A 22735931 I See note Common Stock 2014-12-23 4 P 0 16393 393.9927 A 22752324 I See note Common Stock 2014-12-23 4 P 0 47730 394.8543 A 22800054 I See note Common Stock 2014-12-23 4 P 0 2868 396.6363 A 22802922 I See note Common Stock 2014-12-23 4 P 0 16237 397.7191 A 22819159 I See note Common Stock 2014-12-23 4 P 0 9983 398.1565 A 22829142 I See note Common Stock 2014-12-24 4 P 0 1100 392.7173 A 22830242 I See note Common Stock 2014-12-24 4 P 0 700 393.8886 A 22830942 I See note Common Stock 2014-12-24 4 P 0 890 395.5299 A 22831832 I See note Common Stock 2014-12-24 4 P 0 1700 396.6641 A 22833532 I See note Common Stock 2014-12-24 4 P 0 2067 397.5334 A 22835599 I See note Common Stock 2014-12-24 4 P 0 3300 398.7791 A 22838899 I See note Common Stock 2014-12-24 4 P 0 20245 399.7415 A 22859144 I See note The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). Purchase prices range from $384.00 to $384.81 per share, inclusive. Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,059,592 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Purchase prices range from $385.00 to $385.92 per share, inclusive. Purchase prices range from $386.00 to $386.96 per share, inclusive. Purchase prices range from $387.52 to $388.50 per share, inclusive. Purchase prices range from $388.60 to $389.59 per share, inclusive. Purchase prices range from $389.60 to $390.49 per share, inclusive. Purchase prices range from $391.04 to $391.61 per share, inclusive. Purchase prices range from $392.39 to $393.37 per share, inclusive. Purchase prices range from $393.48 to $394.44 per share, inclusive. Purchase prices range from $394.48 to $395.00 per share, inclusive. Purchase prices range from $395.98 to $396.97 per share, inclusive. Purchase prices range from $396.99 to $397.98 per share, inclusive. Purchase prices range from $397.99 to $398.56 per share, inclusive. Purchase prices range from $392.57 to $393.11 per share, inclusive. Purchase prices range from $393.79 to $393.92 per share, inclusive. Purchase prices range from $395.14 to $395.76 per share, inclusive. Purchase prices range from $396.19 to $397.16 per share, inclusive. Purchase prices range from $397.23 to $398.10 per share, inclusive. Purchase prices range from $398.26 to $399.23 per share, inclusive. Purchase prices range from $399.27 to $400.00 per share, inclusive. /s/ John Felitti, Associate Vice President, Corporate Law, Financial & Securities Law 2014-12-29